908 related articles for article (PubMed ID: 17901791)
1. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media.
Noel GJ; Blumer JL; Pichichero ME; Hedrick JA; Schwartz RH; Balis DA; Melkote R; Bagchi P; Arguedas A
Pediatr Infect Dis J; 2008 Jun; 27(6):483-9. PubMed ID: 18449063
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
4. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
[TBL] [Abstract][Full Text] [Related]
5. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
6. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
Lee PI; Wu MH; Huang LM; Chen JM; Lee CY
J Microbiol Immunol Infect; 2008 Feb; 41(1):54-61. PubMed ID: 18327427
[TBL] [Abstract][Full Text] [Related]
7. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
Pertel PE; Bernardo P; Fogarty C; Matthews P; Northland R; Benvenuto M; Thorne GM; Luperchio SA; Arbeit RD; Alder J
Clin Infect Dis; 2008 Apr; 46(8):1142-51. PubMed ID: 18444848
[TBL] [Abstract][Full Text] [Related]
8. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
Sáez-Llorens X; Castaño E; Wubbel L; Castrejón MM; de Morales I; Vallarino D; de Atencio I; Muñiz L; Olsen K; McCracken GH
Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
[TBL] [Abstract][Full Text] [Related]
9. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
10. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
[TBL] [Abstract][Full Text] [Related]
15. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
16. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.
Noel GJ; Bradley JS; Kauffman RE; Duffy CM; Gerbino PG; Arguedas A; Bagchi P; Balis DA; Blumer JL
Pediatr Infect Dis J; 2007 Oct; 26(10):879-91. PubMed ID: 17901792
[TBL] [Abstract][Full Text] [Related]
18. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
20. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study.
Henry DC; Kapral D; Busman TA; Paris MM
Clin Ther; 2004 Dec; 26(12):2026-33. PubMed ID: 15823766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
